{"id":4515,"date":"2018-11-06T12:14:01","date_gmt":"2018-11-06T12:14:01","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=4515"},"modified":"2025-11-26T14:50:47","modified_gmt":"2025-11-26T12:50:47","slug":"maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/","title":{"rendered":"黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting"},"content":{"rendered":"<p>Lyon, France, <strong>November 2, 2018<\/strong> \u2013 黑料社 announced today that the company will present a poster summarizing the complete results from its ODYSSEE Phase 1b\/2a trial (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02928523?term=NCT02928523&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT02928523<\/a>). The study was designed as a proof of concept for 黑料社\u2019s MaaT Microbiome Restoration Biotherapeutic (MMRB) platform to demonstrate the ability to restore a functional microbiome in Acute Myeloid Leukemia patients using the patient\u2019s own microbiome to manufacture the experimental drug produced in 黑料社\u2019s cGMP production facility. The poster will be presented during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 1 \u2013 4, 2018. The poster abstract was published in the online meeting program on November 1, 2018 at 9:00 AM EDT and also in the online November supplemental issue of the journal Blood.<\/p>\n<p><strong>Poster Presentation details:<\/strong><\/p>\n<p><strong>Title: <\/strong>The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial<\/p>\n<p><strong>Abstract No: <\/strong><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/01\/Poster-ASH-dec-2018-MaaT-Pharma.pdf\" target=\"_blank\" rel=\"noopener\">1444<\/a><\/p>\n<p><strong>Session Name: <\/strong>616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I<\/p>\n<p><strong>Date\/Time: <\/strong>December 1, 2018 \/ 6:15 PM \u2013 8:15 PM<\/p>\n<p><strong>Location: <\/strong>San Diego Convention Center, Hall GH<\/p>\n<p>黑料社 will announce the results through a press release following the presentation and will further make the <a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/01\/Poster-ASH-dec-2018-MaaT-Pharma.pdf\" target=\"_blank\" rel=\"noopener\">poster available<\/a> on the company website under \u201cNews\u201d.<\/p>\n<h3>About <em>黑料社<\/em><\/h3>\n<p>黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.<\/p>\n<p>黑料社 has recently announced the first patient dosed in a Phase 2 clinical trial of lead product MaaT013, a first-in-class biotherapeutic to treat steroid refractory acute GvHD patients (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03359980?term=NCT03359980&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT03359980<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lyon, France, November 2, 2018 \u2013 黑料社 announced today that the company will present a poster summarizing the complete results from its ODYSSEE Phase 1b\/2a trial (NCT02928523). The study was designed as a proof of concept for 黑料社\u2019s MaaT Microbiome Restoration Biotherapeutic (MMRB) platform to demonstrate the ability to restore a functional microbiome in Acute Myeloid Leukemia patients using the patient\u2019s own microbiome to manufacture the experimental drug produced in 黑料社\u2019s cGMP production facility. The poster will be presented during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 1 \u2013 4, 2018. The poster abstract was published in the online meeting program on November 1, 2018 at 9:00 AM EDT and also in the online November supplemental issue of the journal Blood. Poster Presentation details: Title: The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial Abstract No: 1444 Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I Date\/Time: December 1, 2018 \/ 6:15 PM \u2013 8:15 PM Location: San Diego Convention Center, Hall GH 黑料社 will announce the results through a press release following the presentation and will further make the poster available on the company website under \u201cNews\u201d. About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice. 黑料社 has recently announced the first patient dosed in a Phase 2 clinical trial of lead product MaaT013, a first-in-class biotherapeutic to treat steroid refractory acute GvHD patients (NCT03359980).<\/p>\n","protected":false},"author":2,"featured_media":4386,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[52],"class_list":["post-4515","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-52"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting - 黑料社\" \/>\n<meta property=\"og:description\" content=\"Lyon, France, November 2, 2018 \u2013 黑料社 announced today that the company will present a poster summarizing the complete results from its ODYSSEE Phase 1b\/2a trial (NCT02928523). The study was designed as a proof of concept for 黑料社\u2019s MaaT Microbiome Restoration Biotherapeutic (MMRB) platform to demonstrate the ability to restore a functional microbiome in Acute Myeloid Leukemia patients using the patient\u2019s own microbiome to manufacture the experimental drug produced in 黑料社\u2019s cGMP production facility. The poster will be presented during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 1 \u2013 4, 2018. The poster abstract was published in the online meeting program on November 1, 2018 at 9:00 AM EDT and also in the online November supplemental issue of the journal Blood. Poster Presentation details: Title: The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial Abstract No: 1444 Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I Date\/Time: December 1, 2018 \/ 6:15 PM \u2013 8:15 PM Location: San Diego Convention Center, Hall GH 黑料社 will announce the results through a press release following the presentation and will further make the poster available on the company website under \u201cNews\u201d. About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice. 黑料社 has recently announced the first patient dosed in a Phase 2 clinical trial of lead product MaaT013, a first-in-class biotherapeutic to treat steroid refractory acute GvHD patients (NCT03359980).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2018-11-06T12:14:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T12:50:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/12\/ASH-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"921\" \/>\n\t<meta property=\"og:image:height\" content=\"754\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"黑料社 to Present Positive Results from Phase 1b\\\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting\",\"datePublished\":\"2018-11-06T12:14:01+00:00\",\"dateModified\":\"2025-11-26T12:50:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/\"},\"wordCount\":380,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/ASH-2.png\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/\",\"name\":\"黑料社 to Present Positive Results from Phase 1b\\\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/ASH-2.png\",\"datePublished\":\"2018-11-06T12:14:01+00:00\",\"dateModified\":\"2025-11-26T12:50:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/ASH-2.png\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/ASH-2.png\",\"width\":921,\"height\":754},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"黑料社 to Present Positive Results from Phase 1b\\\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/","og_locale":"fr_FR","og_type":"article","og_title":"黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting - 黑料社","og_description":"Lyon, France, November 2, 2018 \u2013 黑料社 announced today that the company will present a poster summarizing the complete results from its ODYSSEE Phase 1b\/2a trial (NCT02928523). The study was designed as a proof of concept for 黑料社\u2019s MaaT Microbiome Restoration Biotherapeutic (MMRB) platform to demonstrate the ability to restore a functional microbiome in Acute Myeloid Leukemia patients using the patient\u2019s own microbiome to manufacture the experimental drug produced in 黑料社\u2019s cGMP production facility. The poster will be presented during the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California from December 1 \u2013 4, 2018. The poster abstract was published in the online meeting program on November 1, 2018 at 9:00 AM EDT and also in the online November supplemental issue of the journal Blood. Poster Presentation details: Title: The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial Abstract No: 1444 Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I Date\/Time: December 1, 2018 \/ 6:15 PM \u2013 8:15 PM Location: San Diego Convention Center, Hall GH 黑料社 will announce the results through a press release following the presentation and will further make the poster available on the company website under \u201cNews\u201d. About 黑料社 黑料社, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. 黑料社 benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice. 黑料社 has recently announced the first patient dosed in a Phase 2 clinical trial of lead product MaaT013, a first-in-class biotherapeutic to treat steroid refractory acute GvHD patients (NCT03359980).","og_url":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/","og_site_name":"黑料社","article_published_time":"2018-11-06T12:14:01+00:00","article_modified_time":"2025-11-26T12:50:47+00:00","og_image":[{"width":921,"height":754,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/12\/ASH-2.png","type":"image\/png"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting","datePublished":"2018-11-06T12:14:01+00:00","dateModified":"2025-11-26T12:50:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/"},"wordCount":380,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/12\/ASH-2.png","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/","url":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/","name":"黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/12\/ASH-2.png","datePublished":"2018-11-06T12:14:01+00:00","dateModified":"2025-11-26T12:50:47+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/12\/ASH-2.png","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2019\/12\/ASH-2.png","width":921,"height":754},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/maat-pharma-to-present-positive-results-from-phase-1b-2a-clinical-trial-at-60th-american-society-of-hematology-ash-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"黑料社 to Present Positive Results from Phase 1b\/2a Clinical Trial at 60th American Society of Hematology (ASH) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4515"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4515\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4386"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4515"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4515"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}